Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free Diet

NCT07298343 is registered in ClinicalTrials.gov with Dr. Falk Pharma GmbH as lead sponsor.

NCT NCT07298343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07298343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free Diet
Lead sponsor
Dr. Falk Pharma GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
June 10, 2024
Completion date
August 31, 2027
Enrollment
356 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease